Prostate Knowledge

New study compares long-term side effects from different prostate cancer treatments

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Prostate cancer therapies are improving over time. But how do the long-term side effects from the various options available today compare? Results from a newly published study are providing some valuable insights. Investigators at Vanderbilt University and the University of Texas MD Anderson Cancer Center spent five years tracking the sexual, bowel, urinary, and hormonal […]

African American and white men who receive comparable treatments for prostate cancer have similar survival

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Last year, we reported on two studies showing that African American men respond at least as well as white men to prostate cancer treatments given in clinical trials. Nationally, African Americans with prostate cancer are more than twice as likely to die of the disease as their white counterparts, and that has fueled speculation that […]

Researchers urge prostate cancer screening for men with BRCA gene defects

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Prostate cancer screening with the prostate-specific antigen (PSA) test has been criticized for flagging too many slow-growing tumors that might never be life-threatening. But some men have inherited gene defects that boost their risk of developing prostate cancers that can be quite aggressive. Is PSA screening particularly well-suited for these genetically defined groups? New research […]

Most men can hold off on radiation after prostate cancer surgery

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Decisions about follow-up care after prostate cancer surgery sometimes involve a basic choice. If the cancer had features that predict it could return, doctors will likely recommend radiation therapy. But when should a man get that treatment? Should he get the radiation right away, even if there’s no evidence of cancer in the body (this […]

Darolutamide approved for nonmetastatic castration-resistant prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Sometimes after finishing prostate cancer treatment, men get an unwelcome surprise: their prostate-specific antigen (PSA) levels creep higher, suggesting tumors too small to be seen lurk somewhere in the body. This leads to several options. Doctors can continue to monitor a man’s condition with imaging scans. Or, given the anxiety associated with rising PSA, they […]

Common hormonal treatments linked to abnormal heart rhythms and sudden death in men being treated for prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Treatments for advanced prostate cancer that suppress testosterone, a hormone (also called an androgen) that drives the malignant cells to grow and spread, are collectively referred to as androgen deprivation therapies, or ADT. These therapies can significantly extend lifespans in men who have the disease, but they also have a range of challenging side effects. […]

Popular drugs used for treating enlarged prostates associated with high-grade prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

If a man has an enlarged prostate, there’s a good chance he’ll be treated with a type of drug called a 5-alpha reductase inhibitor (5-ARI). These drugs shrink the gland to improve urinary flow, and the approved forms used for treating enlarged prostates come in two varieties: Proscar (finasteride) and Avodart (dutasteride). However, a side […]

From Brexit to TRexit: Transperineal biopsies pose a challenge to the traditional transrectal biopsy method

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

By now most of us are familiar with Brexit, the UK’s pending divorce with the European Union. But in a play on that term, British doctors are also moving towards an exit they’ve dubbed “TRexit” from the most common sort of prostate biopsy: the transrectal ultrasound guided biopsy, or TRUS. Men who test positive on […]

Can a man with abnormal PSA and a negative diagnostic MRI avoid a prostate biopsy? It’s debatable

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Not long ago, an abnormal PSA reading would be followed right away by a standard biopsy to search for potential cancer in the prostate. During such a procedure, doctors take 10 to 12 samples of the prostate from various locations while looking at the gland with an ultrasound machine. These days, however, men with high […]

Undoing the harm: Tapering down from high-dose opioids

Scott Weiner, MD

Contributor

The CDC’s 2016 Guideline on Prescribing Opioids for Chronic Pain was created to help providers and patients manage medication treatment at safe levels and avoid dependence. Any plan to taper medication dosage should be personalized to the patient’s needs.